Mirjana Poropat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mirjana Poropat has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Danica Batinić
University Zagreb School of Medicine, Department of Pediatrics, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
1 shared publication - Daniel Turudic
Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia
1 shared publication - Danko Milošević
Nika za pedijatriju Klinički bolnički centar Zagreb Danka
1 shared publication - Ernest Bilić
Department of Pediatrics, Division of Hematology and Oncology, Clinical Medical Centre Zagreb, University of Zagreb School of Medicine School of Medicine, Kišpatićeva 12, Zagreb, 10000, Croatia
1 shared publication - Ranka Štern-Padovan
Department for Diagnostic and Interventional Radiology, Clinical Medical Centre Zagreb, University of Zagreb School of Medicine, Kišpatićeva 12, Zagreb, 10000, Croatia
1 shared publication - Slobodan Galić
Department of Pediatrics, University Hospital Center Zagreb, 10000 Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 17 December 2014
- Published by Springer Nature in BMC Pediatrics
- Vol. 14 (1) , 315
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only three cases are reported in children, all of them with hemophilia A. We present unique case of patient with hemophilia B and high titer inhibitors to coagulation FIX, who developed severe renal damage due to thromboembolic event during rFVIIa therapy, associated with unsuspected renovascular anomalies. Caution is necessary if hematuria B requires administration of rFVIIa. US color doppler renal imaging before and after drug administration should be sufficient as an early warning.
- 17 December 2014
- Published by Springer Nature in BMC Pediatrics
- Vol. 14 (1) , 315
Open AccessRenal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only three cases are reported in children, all of them with hemophilia A. We present unique case of patient with hemophilia B and high titer inhibitors to coagulation FIX, who developed severe renal damage due to thromboembolic event during rFVIIa therapy, associated with unsuspected renovascular anomalies. Caution is necessary if hematuria B requires administration of rFVIIa. US color doppler renal imaging before and after drug administration should be sufficient as an early warning.